Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of the study is to find out if the study drugs Avelumab, Cetuximab, and Palbociclib will slow or stop your cancer from getting worse, and whether it causes side effects. The second purpose is to measure whether your cancer responds to the study drugs Avelumab, Cetuximab, and Palbociclib. The study drugs Avelumab, Cetuximab, and Palbociclib are types of drugs called a monoclonal antibody. Monoclonal antibodies are made to recognize, target, and bind to specific proteins on cells the building blocks making up your tissues.
Head and Neck Squamous Cell Carcinoma
DRUG: Avelumab|DRUG: Palbociclib|DRUG: Cetuximab
maximum tolerated dose, maximum tolerated dose/recommended phase II dose., 12 months
Overall response rate, Determined by RECIST 1.1, through study completion, an average of 3 years|progression free survival, progression free survival, through study completion, an average of 3 years|overall survival, overall survival, through study completion, an average of 3 years|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, through study completion, an average of 3 years
This is an open-label phase I trial with a 3+3 dose escalation design. All patients will receive avelumab, cetuximab, and palbociclib. This study will enroll patients with head and neck squamous cell carcinoma not amenable to curative intent therapy.

Treatment will be administered in 28 day cycles with a pre-defined dose escalation schedule.